LensGen® Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directors
Summary
“We are pleased that LensGen continues to make excellent progress towards advancing their IDE approval process and position the company for initiation of Phase I FDA study,” said Akiteru Furukawa, General Manager, Hoya Corporate Venture Capital Group. With over 40 years of experience building and advancing world-class ophthalmic organizations, Jim Mazzo joins the LensGen Board of Directors as one of the industry’s best-known, most respected and charismatic leaders. “I am looking forward to working with this innovative and dedicated team of professionals and leading surgeons around the world to bring better lens implant treatment options to patients.” “We are delighted to attract additional investment from an experienced ophthalmology and corporate strategic investor like HOYA in order to advance into the pivotal stage of our FDA clinical study and bring to market an innovative and elegant solution for treating cataracts and presbyopia,” said Ramgopal Rao, CEO and Founder of LensGen. With its innovative Juvene® fluid-optic intraocular lens the company aims to treat vision correction errors and provide spectacle independence to patients affected by cataracts and/or presbyopia. In the information technology field, we provide products such as optical lenses, photomasks and blanks used in the manufacturing process for semiconductor and LCD/OLED devices, text to speech, human resources and other software solutions and critical components for the mass memory and cloud storage industries.